|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Collaborator: |
Atopic Dermatitis and Vaccinia Network |
| Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00550316 |
Purpose
People with atopic dermatitis (AD), also known as eczema, experience hot, dry, scaly skin with severe itching. In addition, people with AD are prone to skin infections and inflammation. Little is known about the causes of AD. The purpose of this study is to create a registry of people both with and without AD. This registry will be used as a source of data to determine genetic markers for AD and also as a potential participant database for future studies.
| Condition |
|---|
|
Atopic Dermatitis |
| Study Type: | Observational |
| Study Design: | Case Control, Cross-Sectional |
| Official Title: | ADVN Biomarker Registry Study |
Blood samples
| Estimated Enrollment: | 1000 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | January 2010 |
| Groups/Cohorts |
|---|
|
1
Participants with AD who currently have or have had Eczema Herpeticum (EH)
|
|
2
African Americans and Caucasians of non-Hispanic lineage with AD who do not have and have never had EH
|
|
3
Participants with AD who currently have or have had Eczema Vaccinatum (EV)
|
|
4
Participants with AD who do not have and have never had EV despite receipt of the smallpox vaccination
|
|
5
Participants with AD and a currently active case of Molluscum Contagiosum (MC)
|
|
6
Participants without AD but who currently have an active case of MC
|
|
7
Healthy participants with currently active or history of AD, EH, EV, or MC
|
AD is a chronic, inflammatory skin condition characterized by itching, flaking skin, and a tendency to acquire viral skin infections. The causes and complications of AD are not well understood. The purpose of this study is to establish a registry of people, both with AD and without AD, to help determine genetic markers of AD as well as to contact for participation in future AD studies.
This study will consist of one visit at which the participant's complete medical history will be taken, and blood collection may occur. Participants may be contacted at a later date to participate in future AD studies.
Eligibility| Ages Eligible for Study: | 8 Months to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Participants with and without AD who meet the participation criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Judy Lairsmith | (303) 270-2413 | lairsmithj@NJHealth.org |
| United States, California | |
| Univeristy of California at San Diego | Recruiting |
| La Jolla, California, United States | |
| Contact: Doru Alexandrescu, MD 858-657-7192 dtalexandrescu@ucsd.edu | |
| Principal Investigator: Richard Gallo, MD, PhD | |
| Sub-Investigator: Tissa Hata, MD | |
| United States, Colorado | |
| National Jewish Health | Recruiting |
| Denver, Colorado, United States | |
| Contact: Judy Lairsmith 303-270-2413 lairsmithj@NJHealth.org | |
| Principal Investigator: Donald Leung, MD, PhD | |
| Sub-Investigator: Mark Boguniewicz, MD | |
| United States, Illinois | |
| Northwestern University | Recruiting |
| Chicago, Illinois, United States | |
| Contact: Reena Vaid 773-327-3326 rvaid@childrensmemorial.org | |
| Principal Investigator: Amy Paller, MD | |
| Children's Memorial Hospital | Recruiting |
| Chicago, Illinois, United States | |
| Contact: Reena Vaid 773-327-3326 rvaid@childrensmemorial.org | |
| Principal Investigator: Amy Paller, MD | |
| United States, Massachusetts | |
| Children's Hospital Boston | Recruiting |
| Boston, Massachusetts, United States | |
| Contact: Lisa Heughan 617-355-6127 lisa.heughan@childrens.harvard.edu | |
| Principal Investigator: Lynda Schneider, MD | |
| United States, New York | |
| University of Rochester Medical Center | Recruiting |
| Rochester, New York, United States | |
| Contact: Lorianne Stubbs 585-275-0374 Lorianne_Stubbs@urmc.rochester.edu | |
| Principal Investigator: Lisa Beck, MD | |
| United States, Oregon | |
| Oregon Health & Sciences University | Recruiting |
| Portland, Oregon, United States | |
| Contact: Susan Tofte 503-494-6445 toftes@ohsu.edu | |
| Principal Investigator: Jon Hanifin, MD, PhD | |
| Sub-Investigator: Eric Simpson, MD | |
| Principal Investigator: | Lisa Beck, MD | University of Rochester |
More Information
| Responsible Party: | DAIT/NIAID ( Associate Director, Clinical Research Program ) |
| Study ID Numbers: | DAIT ADVN REG 03, Contract #: HHSN266200400033 |
| Study First Received: | October 25, 2007 |
| Last Updated: | May 26, 2009 |
| ClinicalTrials.gov Identifier: | NCT00550316 History of Changes |
| Health Authority: | United States: Federal Government |
|
Atopic Dermatitis Eczema Eczema Herpeticum Molluscum Contagiousum |
Herpes Simplex Eczema Vaccinatum Vaccinia |
|
Hypersensitivity Dermatitis, Atopic Immune System Diseases Genetic Diseases, Inborn Skin Diseases |
Hypersensitivity, Immediate Skin Diseases, Eczematous Skin Diseases, Genetic Dermatitis |